Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zabinostat - IngenOx Therapeutics

Next Previous
Drug Profile

Zabinostat - IngenOx Therapeutics

Alternative Names: AZD 9468; CXD101; Zabadinostat

Latest Information Update: 27 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer Cancer Research UK; IngenOx Therapeutics; Merck Sharp & Dohme; National Institute for Health Research; Nuance Biotech; Oxford University Hospitals NHS Trust; Syneos Health; University College London
  • Class Anti-inflammatories; Antihyperlipidaemics; Antineoplastics; Cardiovascular therapies; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Peripheral T-cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer; Hodgkin's disease; Liver cancer; Peripheral T-cell lymphoma
  • Phase I/II Diffuse large B cell lymphoma
  • No development reported Lymphoma

Most Recent Events

  • 01 Mar 2026 ImmunityBio plans a phase I trial for Pancreatic cancer (Neoadjuvant therapy, Combination therapy, Late-stage disease, First line therapy) in March 2026 (IV) (NCT07488884)
  • 28 Aug 2025 No recent reports of development identified for phase-I development in Lymphoma(Second-line therapy or greater) in China (PO, Capsule)
  • 26 Feb 2025 Efficacy data from a phase II trial in Liver cancer released by IngenOx

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top